The headline reads as positive (86% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › CRL
Charles River Laboratories Inte (CRL) stock analysis
WEAK BUY 17% confidence · analysed Oct 14, 2026
On Oct 14, 2026, our model rated Charles River Laboratories Inte (CRL) WEAK BUY with 17% confidence at a price of $299.02. That means the signals lean positive, but they are mixed, so conviction is low.
SectorHealthcare
IndustryDiagnostics & Research
Market cap14.40B
Analysed price$299.02
Technical picture
The 14-day RSI is 65, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.7x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $228.88 and the swing low is $146.33; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The PEG ratio is 0.12, which looks cheap relative to its expected growth.
The company reports a profit margin of -6.0% and revenue growth of -2.7%.
In its latest quarter it earned $3.02 per share, which beat the $2.74 analysts expected, with revenue -2.7% year over year.
Wall Street's average rating is 1.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $313.20.
The next earnings report is expected around Nov 4, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $302.04, a target of $313.20 (+3.7%) and a stop-loss at $278.94 (-7.6%).
That is a reward-to-risk ratio of about 0.5 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Oct 24, 2026 whatever the price does.
Entry$302.04
Target$313.20
Stop-loss$278.94
Reassess byOct 24, 2026
Research notes
CRL’s bull case has strengthened: analysts remain broadly bullish, with the average target at $324.87 and Morgan Stanley raising its target to $340, while the company’s 2030 plan calls for 5–7% organic revenue growth and potential margin benefits from internalizing non-human-primate supply. The bear case is that the stock’s rapid advance—about 29% over 90 days to roughly $299—has left limited upside, while weak Discovery and Safety Assessment demand, pricing pressure, thin profitability, and premium valuation remain risks. A new catalyst is the Apollo Orchestrate launch with Autolomous, which could improve automation and efficiency in biologics quality-control laboratories. The latest public information and price action agree with the prior positive view, although the rally has made valuation and execution risks more consequential.
The model's one-paragraph read
Leans BUY — composite score +0.17 (WEAK BUY). Technicals: RSI 64.58, MACD bullish, price above SMA50. Fundamentals: PEG 0.12, margin -6.0%, revenue growth -2.7%. Financial results: YoY revenue -2.7%, last EPS surprise +10.2%, next earnings 2026-11-04. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bearish order block, sitting inside an unfilled bullish fair value gap, sitting inside an unfilled bearish fair value gap. FinGPT news read: neutral. Memory: 1 prior look(s). Internet research: CRL’s **bull case** has strengthened: analysts remain broadly bullish, with the average target at $324.87 and Morgan Stanley raising its target to $340, while the company’s 2030 plan calls for 5–7% organic revenue growth and potential margin benefits from internalizing non-human-primate supply. The **bear case** is that the stock’s rapid advance—about 29% over 90 days to roughly $299—has left limited upside, while weak Discovery and Safety Assessment demand, pricing pressure, thin profitability, and premium valuation remain risks. A new catalyst is the Apollo Orchestrate launch with Autolomous, which could improve automation and efficiency in biologics quality-control laboratories. The latest public information and price action **agree with the prior positive view**, although the rally has made valuation and execution risks more consequential. Suggested levels: entry $302.04, target $313.2, stop-loss $278.94, exit by 2026-10-24 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for CRL
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 14, 2026 | WEAK BUY | 17% | $299.02 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on CRL
Oct 14, 2026 · From Charles Schwab to DoorDash: Why these bargain stocks could lead the market higher
- Oct 14, 2026: Charles Schwab and DoorDash ranked among bargain stocks that could lead the market higher (MarketWatch Top)
- Oct 14, 2026: From Charles Schwab to DoorDash: Why these bargain stocks could lead the market higher (MarketWatch Top)
- Oct 14, 2026: Charles River partners with Magellan Stem Cells on cell therapy (Pharmaceutical Technology)
Other Healthcare stocks we cover
CVS · CYTK · DVA · ETON · EVH · FTRE · HALO · HUM · IART · IBRX · ICLR · IRWD
Frequently asked questions
Is CRL a buy right now?
As of Oct 14, 2026, our automated model rates Charles River Laboratories Inte (CRL) WEAK BUY with 17% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for CRL?
The model's most recent plan targets $313.20 with a stop-loss at $278.94, from an entry near $302.04.
When does Charles River Laboratories Inte report earnings next?
The next earnings report is expected around Nov 4, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.